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Abstract 
Background 
Public health benefits from research often rely on the use of data from personal 
medical records.  When neither patient consent nor anonymisation is possible, the 
case for accessing such records for research purposes depends on an assessment of the 
probabilities of public benefit and individual harm.  
 
Methods 
In the late 1990s, we carried out an observational study which compared the care 
given to affluent and deprived women with breast cancer.  Patient consent was not 
required at that time for review of medical records, but was obtained later in the 
process prior to participation in the questionnaire study. We have re-analysed our 
original results to compare the whole sample with those who later provided consent. 
 
Results 
Two important findings emerged from the re-analysis of our data which if presented 
initially would have resulted in insufficient and inaccurate reporting.  Firstly, the 
reduced dataset contains no information about women presenting with locally 
advanced or metastatic cancer and we would have been unable to demonstrate one of 
our initial key findings: namely a larger number of such women in the deprived 
group.  Secondly, our re-analysis of the consented women shows that significantly 
more women from deprived areas (51 v 31%, p=0.018) received radiotherapy 
compared to women from more affluent areas.  Previously published data from the 
entire sample demonstrated no difference in radiotherapy treatment between the 
affluent and deprived groups.  
 Conclusion 
The risk benefit assessment made regarding the use of medical records without 
consent should include the benefits of obtaining research evidence based on 100% of 
the population and the possibility of inappropriate or insufficient findings if research 
is confined to consented populations.  
Background 
Many research studies which have led to improvements in public health benefits have 
relied on the use of data from personal medical records. [1] In particular, retrospective 
review of medical records has been carried out for many years in order to answer 
questions related to the coverage and equity of health care.  When neither patient 
consent nor anonymisation is possible, the case for accessing such records for 
research purposes depends on an assessment of the probabilities of public benefit and 
individual harm.  The past decade has seen a shift in attitude towards using data 
derived from medical records without patient consent.  Previously, ethics approval for 
studies involving retrospective use of data was based on a range of considerations 
including the relevance and usefulness of the research question, scientific peer review, 
suitable data collection methods and data security.  Subject to these caveats, many 
studies have been carried out, which included almost 100% coverage of the target 
population. 
 
In the current ethical and research governance climate, primacy tends to be given to 
considerations of individual autonomy [2] over considerations of public benefit.  It 
has become a common view that explicit consent is required in order to use 
identifiable personal data for research. [3]  However, a growing body of evidence 
demonstrates that studies relying solely on patient consent may produce findings that 
are unrepresentative [4-7] or misleading. [8] In some instances, ethics committees 
have permitted an opt-out arrangement where researchers have been required to first 
contact the patient for permission to review records, and asking them to reply if they 
object to their records being reviewed; this is not yet in universal practice, particularly 
in cases where, due to the requirements of the particular study, records cannot be 
anonymised.  These arguments have not however been applied to audit which is 
considered an essential part of good clinical practice, and for which patient consent is 
not required.  
 
Recent analysis of changes in relevant legislation brought about by the Data 
Protection Act and the Humans Right Act, suggest that these laws need not prevent 
researchers from using identifiable data without consent, provided there is a clear 
public benefit. [9]  In this paper, we provide further evidence of how limiting the use 
of identifiable patient data may act against the public interest.   
 
Methods 
In the late 1990s, we compared the care provided by the NHS in Glasgow for all 421 
women with breast cancer living in affluent and deprived areas. [10-12]  Population 
coverage by the study was 100% based on ascertainment of cases from cancer 
registration and 99% based on hospital case notes.  We then opted to concentrate on 
patients who had operable breast cancer (n=366) and obtained general practice 
records relating to 76% (n=278) of these women.  A postal questionnaire was sent to 
women whom we knew to be alive at the time of the general practice records data (n= 
218) collection and whose general practitioners confirmed they were alive and well 
just prior to posting the questionnaire. Cases were “lost” for the purpose of this 
retrospective study at two points: at the general practice data collection stage and at 
the questionnaire stage.  The issue at the point of reviewing general practice records 
was that we required practices to facilitate us collecting data from their records; a 
number of practices did not engage with the study with respect to this after many 
contacts by letter, fax and phone and so we were only able to review 78% of potential 
records: we did not request practices to obtain consent from patients.   As we were 
contacting women several years after their diagnosis of cancer, we decided to check 
with general practitioners before sending out questionnaires as to whether the women 
were alive and well.   
 
Ethical approval was obtained for the study, which combined comprehensive record 
review with a patient questionnaire five years after diagnosis.  Patient consent was not 
required at that time for the review of records, but was given later in the process when 
women were contacted and invited to participate in the questionnaire study.  [12]  In 
this paper, we summarise the original findings, and add a parallel set of findings, 
based only on review of the medical records of the 177 women who took part in the 
questionnaire survey, and assuming that, if they had been asked, these women would 
also have consented to the review of their medical records.  For the purpose of clarity, 
these women are referred to here as the ‘consented’ sample.  
 
Results  
In our original study, the virtually complete sample of hospital records allowed us to 
show equitable provision of the main treatments for breast cancer – surgery, 
radiotherapy and chemotherapy – according to tumour stage.  We also showed that 
pathological staging information was not available for 12% of women, mostly from 
deprived areas, who presented with more locally advanced or metastatic tumours. [10, 
11]  
 
In the new analyses reported here, restricted to the hospital records of the women who 
gave consent by returning questionnaires, two findings emerged which are different 
from those we reported earlier.   
 
First, although the reduced dataset shows similar findings to the main study (with 
wider confidence limits) with respect to treatments by tumour staging in women 
presenting with early tumours, it contains no information about the 12% of women 
presenting with locally advanced or metastatic cancer (Table 1).   
 
The second different finding shows that significantly more women from deprived 
areas (51 v 31%, p=0.018) received radiotherapy compared to women from more 
affluent areas (Table 2).  Other findings, although with a smaller sample, were not 
significantly different from those originally found and published.   
 
Although the response rate to the questionnaire was 81%, the women returning a 
questionnaire comprised only 48% of the original population of women with early 
breast cancer. Missing categories comprised women who had died (n=20) or left the 
area (n=3), and practices which declined to take part in study (n= 19), did not respond 
to requests to see records after numerous contacts (n= 46), or did not confirm that the 
patient was alive and well at time of survey (n= 60).  
 
 
Discussion 
Main findings of this study 
In re-analysing the data from our original study, we have demonstrated different 
results based on the virtually complete original patient sample and the reduced 
consented sample.  These differences illustrate some of the consequences and 
challenges of confining research using personal medical records to patients who have 
given explicit consent.  
 
The original analyses, based on records review without patient consent, provided 
largely reassuring information for the NHS, concerning the equity of provision of 
major treatments for women with breast cancer, while avoiding the uncertain, 
incomplete and potentially spurious nature of results based on partial data.  The 
information regarding clinical staging which we obtained from medical records, and 
which had been missed in a previous study based on pathological records, [13] is an 
important research finding and has contributed to the debate regarding the reasons for 
the poorer survival of women form socio-economically deprived areas with breast 
cancer.   
 
The purpose of this part of the original study was to ensure comparability with 
previous work by Carnon et al [13].  They studied the relationship between socio-
economic deprivation and pathological prognostic factors in women with breast 
cancer, in an attempt to explain the known poorer survival in socio-economically 
deprived areas.  They reported that this survival difference was not related to the stage 
of disease at the time of presentation.  We confirmed their findings [10] and also 
produced the new information that more women from deprived areas compared to 
affluent areas presented with locally advanced or metastatic tumours.  This is a small, 
but important group of patients, whose exclusion from case series can produce 
misleading results.  The earlier study [13] had been a study of pathological records 
and so had not included those patients who did not proceed to surgery and therefore 
for whom prognostic pathological factors were not available.  Although many of the 
woman with advanced or metastatic cancer would have been deceased by the time of 
our data collection and so we would likely have been able to obtain their data without 
consent, we would argue that having the benefit of the whole sample enabled us to 
produce these comparisons with some confidence. 
 
With respect to our second finding reported here, it is likely, had we published the 
spurious finding, based on smaller numbers, regarding access to radiotherapy that it 
0could have prompted unnecessary concern, and further research relating to how well 
women were informed about treatment options, and also about potential inappropriate 
exposure to radiotherapy.    
 
Limitations of this study 
This study presents a hypothetical worst-case scenario based on a number of 
assumptions.  Our initial assumption is that our study is less likely to receive ethical 
approval in the current climate.  However, some ethics committees may be content to 
provide ethical approval for a retrospective study of this nature carried out by a 
suitably qualified researcher within an appropriate context.  In addition, the missing 
data from Table 1 may have been available from death records, to which such 
stringent conditions may not be applied.  We have also assumed that the women who 
completed questionnaires are likely to have consented to review of their medical 
records.  This assumption is likely to have under-estimated the level of consent as 
women who did not complete the questionnaire may still have been willing for their 
records to be reviewed.   
A further limitation is that before we were able to ask patients to take part in the study 
by completing the questionnaire, there was a degree of ‘gate-keeping’ by general 
practitioners who could either not engage with the study or decided that their patient 
wasn’t suitable to be included.  We were unable to determine which of these 
explanations was most pertinent in this study.  Gate keeping by clinicians is a feature 
of studies from health service lists, and may have both positive and negative aspects 
from a research point of view.  On the one hand, clinicians often screen potential lists 
of participants to exclude approaches in cases of severe illness or other circumstances 
where an approach would be inappropriate; on the other hand, clinicians may have no 
interest in facilitating research and relegate this task below competing demands on 
their time. In either situation, the net effect in a study such as ours is to increase loss 
to follow-up.  The role that clinicians may have in gate-keeping in this way is an 
important and under-researched area.  
 
Comparison with other studies 
This study adds to a growing body of evidence regarding the implications of 
confining research to data for which expressed and specific consent has been given.  
Others have shown that consented populations are likely to be unrepresentative by age 
or gender [5-7] or may have different clinical outcomes [4] [8].  We have added to 
this by demonstrating the potential for erroneous conclusions.   
 
In retrospective studies, the proportion of patients who give informed consent for 
research access to their records is affected mainly, not by their individual responses, 
but by the numbers whom it is possible to contact.  Obtaining research evidence based 
on 100% of the population may therefore be impossible without the use of identifiable 
data from medical records.  Surveys have shown that most of the public considers the 
use of identifiable data by cancer registries acceptable. [14] However others have 
shown that there is some public concern about the use of data without consent and 
demonstrated the need for further research in this area.  [15] 
 
Implications of this study 
Analyses confined to the hospital records of women who consented to the postal 
questionnaire survey, showed a spurious finding concerning the provision of 
radiotherapy for women from deprived areas, and uncertainty concerning the general 
provision of care, due to small sample size.  It can therefore be argued that requiring 
informed consent for research based on patient records may act against the public 
interest in obtaining information concerning the success or failure of health policies to 
provide equitable care, according to need. Furthermore our main finding that the NHS 
provides equitable treatment for women with breast cancer would have been much 
less authoritative had it been based on smaller numbers.  
 
If this work were considered to be audit rather than research the issues raised here 
would have been irrelevant.  We viewed it to be research, as did several journals [10-
12] because we were asking a new question of data collected for clinical purposes.  
There may be other examples where the boundary between audit and research is 
blurred sufficiently for research to be carried out in the name of audit, so avoiding this 
difficulty.  This is confusing at best and unethical at worst.  
 
Conclusions 
It is debatable whether such our original study would obtain ethical approval in the 
current climate, but if the NHS is to provide and monitor care for 100% of the 
population, it needs information from studies of this type.  Although anonymisation of 
patient records should be carried out whenever possible, many research studies 
require re-identification of patients in a way that anonymisation would make 
impossible.  We propose that research studies based on medical records, for the 
purpose of reviewing the coverage and equity of health care should, with appropriate 
safeguards, be recognised as a class of study for which individual patient consent is 
not required.  With appropriate publicity, explanation, discussion and debate, we 
believe it should be possible to obtain public support for this approach.  
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Table 1: Pathological prognostic factors and clinical stage at presentation for women with breast cancer living in affluent 
and deprived areas (whole sample and questionnaire respondents)  
 
  
AFFLUENT  
n (%) 
 
 
DEPRIVED  
n (%) 
 
Chi squared test result 
 
 
PATHOLOGICAL PROGNOSTIC FACTORS 
 
 
SIZE* 
WHOLE SAMPLE 
 
n = 136 
CONSENTED 
SAMPLE 
n=72 
WHOLE SAMPLE 
 
n = 194 
CONSENTED 
SAMPLE 
n=91 
WHOLE SAMPLE CONSENTED 
SAMPLE 
0 - 19mm 70 (51.5%) 42 (58.3%) 106 (54.6%) 54 (59.3%) X2 = 0.53 X2 = 0.04 
20 - 49mm 62 (45.6%) 29 (40.3%) 81 (41.8%) 36 (39.6%) DF = 2 DF = 2 
>50mm 4 (2.9%) 
 
1 (1.4%) 7 (3.6%) 
 
1 (1.1%) p = 0.76 p = 0.98 
 
      
GRADE* n = 110 n=59 n = 156 n=72   
1 17 (15.5%) 9 (15.3%) 30 (19.2%) 18 (25.0%) X2 = 0.66 X2 = 1.83 
2 67 (60.9%) 39 (66.1%) 92 (59.0%) 42 (58.3%) DF = 2 DF = 2 
3 26 (23.6%) 
 
11 (18.6%) 34 (21.8%) 
 
12 (16.7%) p = 0.72 p = 0.34 
 
      
NODAL STATUS* n = 128 n=72 n = 196 n=93   
Positive 48 (37.5%) 24 (33.3%) 72 (36.7%) 28 (30.1%) X2= 0.01 X2 = 0.196 
Negative 80 (62.5%) 
 
48 (66.6%) 124 (63.3%) 
 
65 (69.9%) DF = 1 
p = 0.88 
 
DF = 2 
p = 0.736 
CLINICAL STAGE AT PRESENTATION 
 
 
n = 156 
  
n = 260 
   
Early 146 (93.6%) 100% 220 (84.6%) 100% X2 = 7.42 N/A 
Locally advanced or 
metastatic 
10 (6.4%)  40 (15.4%)  DF = 1 
p = 0.006 
 
 
* Size, grade and nodal status only potentially available for the 366 women (146 affluent and 220 deprived) who had operable breast cancer.   
*Total n for whole sample < 366 due to missing data 
**Total n for consented sample < 177 due to missing data 
 Table 2:  Surgical treatment, radiotherapy and adjuvant therapy for women living in affluent and deprived areas (whole 
sample and questionnaire respondents) 
 
  
AFFLUENT 
n (%) 
  
DEPRIVED 
n (%) 
  
Chi squared test 
result  
 
 
 
WHOLE SAMPLE 
 
CONSENTED 
SAMPLE 
 
WHOLE SAMPLE 
 
CONSENTED 
SAMPLE 
 
WHOLE SAMPLE 
 
CONSENTED 
SAMPLE 
BREAST SURGERY n = 142* n = 75** n = 215* n = 97**   
Mastectomy 64 (45.1%) 37 (49.3%) 104 (48.4%) 43 (44.3%) X2  = 0.37 DF = 3 X2  = 0.43 DF = 1 
Conservation 78 (54.9%) 38 (50.7%) 111 (51.6%) 54 (55.7%) p = 0.54 p = 0.54 
AXILLA SURGERY n = 129* n = 70* n = 196 * n = 94**   
Clearance 123 (95.3%) 68 (97.1%) 146 (74.5%) 69 73.4%) X2  = 23.73 DF = 1 X2  = 16.4 DF = 1 
Sampling 6 (4.7%) 2 (2.9%) 50 (25.5%) 25 36.6%) p = 0.0000 p = 0.000 
RADIOTHERAPY n = 146 
54 (37.0%) 
n = 72** 
22 (30.6%) 
n = 220 
90 (40.9%) 
n = 98** 
50 (51.0%) 
X2 = 0.56 DF = 1 
p = 0.45 
X2  = 5.82 DF = 1 
p = 0.018 
CHEMOTHERAPY n = 146 
29 (19.9%) 
n = 75** 
13 (16.9%) 
n = 220 
30 (13.6%) 
n = 100** 
15 (15%) 
X2 = 2.51 DF = 1 
p = 0.11 
X2  = 0.116 DF = 1 
p = 0.84 
Endocrine therapy n = 146 
128 (87.7%) 
n = 77 
71 (92.2%) 
n = 220 
196 (89.1%) 
n = 100 
92 (92.0%) 
X2 = 0.17 DF = 1 
p = 0.67 
X2  = 0.003 DF = 1 
p = 1.0 
*Total n for whole sample < 366 due to missing data 
**Total n for consented sample < 177 due to missing data 
 
 
